ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

CPI-613 in Combination With High Dose ARA-C and Mitoxantrone

Bayard L. Powell, MD
Published Online:6:29 PM, Tue January 6, 2015
Bayard L. Powell, MD, Section Chief, Hematology & Oncology, Director, Leukemia Service, Wake Forest University, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

Clinical Pearls

  • It is feasible to add CPI-613 to high dose ARA-C and mitoxantrone. No additional toxicity was observed.
  • Approximately 50% of patients responded to this combination.
  • Older patients and patients with high-risk cytogenetics typically do not respond well to high dose ARA-C and mitoxantrone. With the addition of CPI-613, the response rate was about the same in these groups compared with the entire population.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.